Meeting patients' needs...
Our vision
...is to be the global leader in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet patient needs.
22 December 2011
Sativex® approved in Sweden for the treatment of spasticity due to Multiple Sclerosis (MS)
12 December 2011
